What is OS Therapies's debt issuance proceeds?

OS Therapies (OSTX) reported debt issuance proceeds of $1.84M in Q1 2026.

What does debt issuance proceeds mean?

Cash received from issuing bonds, notes, term loans, and other debt instruments in the capital markets or from bank lending.

CTO

Citius Oncology, Inc.CTOR

$589.7K—

ImmunityBio, Inc.IBRX

$61K—

Operating income-$10.2M-103%

Net income-$10.4M-168%

EPS (diluted)-$0.27-50.0%

Cash & equivalents$917.6K-69.1%

Total debt$20.0M—

Total equity-$10.8M-159%

Total assets$7.3M+71.7%

Operating cash flow-$4.6M-32.6%

CapEx$316.4K—

Free cash flow-$3.7M—

Market cap$84.62M+66.4%

Enterprise value$103.7M—

Return on equity470%—

Debt / equity-1.8×—

Current ratio0.1×-1.1×

Reported directly by OS Therapies in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromConvertibleDebt.

The official record: OS Therapies’s 10-Q, filed May 18, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is OS Therapies's debt issuance proceeds?: OS Therapies (OSTX) reported debt issuance proceeds of $1.84M in Q1 2026.
What does debt issuance proceeds mean?: Cash received from issuing bonds, notes, term loans, and other debt instruments in the capital markets or from bank lending.